Treatment of pulmonary hypertension

Medical Science Monitor

Volumn 18, Issue 4, 2012, Pages

  Patel, Rajendrakumar ^a   Aronow, Wilbert S ^b   Patel, Laxeshkumar ^c   Gandhi, Kaushang ^b   Desai, Harit ^b   Kaul, Dhiraj ^b   Sahgal, Sumir P ^d  

^a Essen Medical Associates   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c Department of Medicine   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Calcium channel blockers; Endothelin receptor antagonists; Lung transplantation; Phosphodiesterase 5 inhibitors; Prostanoids; Pulmonary arterial hypertension

Indexed keywords

AMBRISENTAN; AMLODIPINE; BOSENTAN; DIGOXIN; DILTIAZEM; DIURETIC AGENT; ILOPROST; NIFEDIPINE; ORAL CONTRACEPTIVE AGENT; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNIPROST; VARDENAFIL; WARFARIN;

ADD ON THERAPY; AEROBIC EXERCISE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULANT THERAPY; ARTHRALGIA; ARTICLE; BLALOCK HANLON OPERATION; BLOOD VESSEL REACTIVITY; CONTINUOUS INFUSION; DIARRHEA; DIGITALIS INTOXICATION; DISEASE SEVERITY; DIURETIC THERAPY; DOPPLER ECHOCARDIOGRAPHY; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; DYSPEPSIA; ENDARTERECTOMY; EPISTAXIS; FLUSHING; GRAM NEGATIVE INFECTION; HEART ARRHYTHMIA; HEART CATHETERIZATION; HEART LUNG TRANSPLANTATION; HEART OUTPUT; HEART RIGHT VENTRICLE FAILURE; HEART SURGERY; HUMAN; HYPERTENSION; HYPOTENSION; JAW PAIN; LIVER FUNCTION; LIVER INJURY; LOW DRUG DOSE; LUNG ARTERY PRESSURE; LUNG EMBOLISM; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; MALE INFERTILITY; MULTICENTER STUDY (TOPIC); NON PULMONARY ARTERIAL HYPERTENSION; OXYGEN SATURATION; OXYGEN THERAPY; PULMONARY HYPERTENSION; PULMONARY THROMBOENDARTERECTOMY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SODIUM RESTRICTION; SURVIVAL RATE; SYNCOPE; TESTIS ATROPHY; THROMBOEMBOLISM; THROMBOSIS; UNSPECIFIED SIDE EFFECT; WALKING;

EID: 84859544966     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.882607     Document Type: Article

References (72)

1. Hoeper MM: Definition, classification, and epidemiology of pulmonary arterial hypertension. Semin Respir Crit Care Med, 2009; 30(4): 369-75
2. Nauser TD, Stites SW: Diagnosis and treatment of pulmonary hypertension. Am Fam Physician, 2001; 63(9): 1789-98
3. Rubin LJ: Primary pulmonary hypertension. N Engl J Med, 1997; 336(2): 111-17
4. Palevsky HI, Fishman AP: Chronic cor pulmonale: etiolology and management. JAMA, 1990; 263(17): 2347-53
5. Galie N, Hoeper MM, Humbert M et al: Guideline for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J, 2009; 30(20): 2493-537
6. Barst RJ, Gibbs JS, Ghofrani HA et al: Updated evidence-based treatment algorithm in pulmonary hypertension. JACC, 2009; 54(Suppl.1): S78-84
7. Badesch DB, Abman S, Ahearn G et al: Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest, 2004; 126(Suppl,1): 35S-62S
8. Rubin LJ, Badesch DB: Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med, 2005; 143(4): 282-92
9. Simonneau G, Galie N, Rubin LJ et al: Clinical classification of pulmonary hypertension. JACC, 2004; 43 (12 Suppl S): 5S-12S
10. Simonneau G, Robbins IM, Beghetti M et al: Updated clinical classification of pulmonary hypertension. JACC, 2009; 54: 43-54
11. Megalla S, Holtzman D, Aronow WS et al: Predictors of cardiac hepatopathy in patients with right heart failure. Med Sci Monit, 2011; 17(10): CR537-41
12. McLaughlin VV, Archer SL, Badesch DB et al: ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association. Developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. JACC, 2009; 53: 1573-619
13. Gaine SP, Rubin LJ: Primary pulmonary hypertension. Lancet, 1998; 352(9129): 719-25
14. Mereles D, Ehlken N, Kreuscher S et al: Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation, 2006; 114(14); 1482-89
15. McLaughlin V, Archer SL, Badesch DB et al: ACCF/AHA 2009 expert consensus document on pulmonary hypertension. JACC, 2009; 53(17): 1573-619
16. Report of the Medical Research Council Working Party: Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet, 1981; 1(8222): 681-86
17. Nocturnal Oxygen Therapy Trial Group: Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med, 1980; 93(3): 391-98
18. Mohr L: Hypoxia during air travel in adults with pulmonary disease. Am J Med Sci, 2008; 335(1): 71-79
19. Rich S, Seidlitz M, Dodin E et al: The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest, 1998; 114: 787-92
20. Weiss BM, Zemp L, Seifert B et al: Outcome of pulmonary vascular disease in pregnancy: a systemic overview from 1978 through 1996. JACC, 1998; 31(7): 1650-57
21. Badesch DB, Abman SH, Simonneau G et al: Medical therapy for pulmonary arterial hypertension: Updated ACCP evidence-based clinical practice guidelines. Chest, 2007; 131(6); 1917-28
22. Sitbon O, Humbert M, Jais X et al: Long term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation, 2005; 111(23): 3105-11
23. Galiè N, Ghofrani HA, Torbicki A et al: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med, 2005; 353(20): 2148-57
24. Jing ZC, Yu ZX, Shen JY et al: Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. AJRCCM, 2011; 183(12): 1723-29
25. Ghofrani HA, Voswinckel R, Reichenberger F et al: Differences in hemodynamic and oxygenation responses to three different phosphodiesterase- 5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. JACC, 2004; 44(7): 1488-96
26. Galie N, Manes A, Branzi A: Prostanoids in pulmonary hypertension. Am J Respir Med, 2003; 2(2): 123-37
27. Barst RJ, Rubin LJ, Long WA et al: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med, 1996; 334(5): 296-302
28. Sitbon O, Humber M, Nunes H et al: Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. JACC, 2002; 40(4): 780-88
29. McLaughlin VV, Shillington A, Rich S: Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation, 2002; 106(12): 1477-82
30. McLaughlin VV, Genthner DE, Panella MM et al: Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med, 1999; 130(9): 740-43
31. Rosenzweig EB, Kerstein D, Barst RJ: Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation, 1999; 99(14): 1858-65
32. Simmonneau G, Barst RJ, Galie N et al: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placedbo-controlled trial. Am J Respir Crit Care Med, 2002; 165(6): 800-4
33. Benza RL, Rayburn BK, Tallaj JA et al: Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan. Chest, 2008; 134(1): 139-45
34. Barst R, Galie N, Naeije R et al: Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J, 2006; 28(6): 1195-203
35. Tapson VF, Gomberg-Maitland M, McLaughlin M et al: Safety and efficacy of iv treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open label, 12-week trial. Chest, 2006; 129(3): 683-88
36. Gomberg-Maitland M, Tapson VF, Benza Rl et al: Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med, 2005; 172(12): 1586-89
37. Centers for Disease Control and Prevention: Bloodstream infections among patients treated with intravenous epoprostenol to intravenous treprostinil for pulmonary arterial hypertension-seven sites, United States, 2003-2006. MMWR Morb Mortal Wkly Rep, 2007; 56: 170-72
38. Doran AK, Ivy DD, Barst RJ et al: Guidelines for the prevention of central venous catheter-related bloodstream infections with prostanoids therapy for pulmonary arterial hypertension. Int J Clin Pract Suppl, 2008; 160: 5-9
39. Olschewski H, Ghofrani HA, Walmrath D et al: Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med, 1999; 160(2): 600-7
40. Olschewski H, Walmrath D, Schermuly R et al: Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med, 1996; 124(9): 820-24
41. Hoeper MM, Schwarze M, Ehlerding S et al: Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med, 2000; 342(25): 1866-70
42. Olschewski H, Simonneau G, Galie N et al: Inhaled iloprost for severe pulmonary hypertension. N Engl J Med, 2002; 347(5): 322-29
43. McLaughlin VV, Oudiz RJ, Frost A et al: Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med, 2006; 174(11): 1257-63
44. Optiz CF, Wensel R, Winkler K et al: Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J, 2005; 26(18): 1895-902
45. Galiè N, Grigioni F, Bacchi-Reggiani L et al: Relation of endothelin-1 to survival in patients with primary pulmonary hypertension. Eur J Clin Invest, 1996; 26(Suppl.1): A48. Abstract
46. Chen SJ, Chen YF, Meng QC et al: Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol, 1995; 79(6): 2122-31
47. Rubin LJ, Badesch DB, Barst RJ et al: Bosetan therapy for pulmonary arterial hypertension. New Engl J Med, 2002; 346(16): 1258
48. Galie N, Beghetti M, Gatzoulis MA et al: Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation, 2006; 114(1): 48-54
49. Galie N, Rubin LJ, Hoeper M et al: Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind randomized controlled trial. Lancet, 2008; 371(9630): 2093-100
50. McLaughlin VV, Sitbon O, Badesch DB et al: Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J, 2005; 25(5): 244-49
51. Sitbon O, McLaughlin VV, badesch DB et al: Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax, 2005; 60(12): 1025-30
52. Barst RJ, Langleben D, Frost A et al: Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med, 2004; 169(4): 441-47
53. Barst RJ, Langleben D, Badesch D et al: treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. JACC, 2006; 47(10): 2049-56
54. Galie N, Badesch D, Oudiz R et al: Ambrisentan therapy for pulmonary arterial hypertension. JACC, 2005; 46(3): 529-35
55. Galie N, Olschewski H, Oudiz RJ et al: Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebocontrolled, multicenter, efficacy (ARIES) study 1 and 2. Circulation, 2008; 117: 3010-19
56. Klinger JR, Oudiz RJ, Spence R et al: Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension. Am J Cardiol, 2011; 108: 302-7
57. FDA drug safety communication: liver injury warning to be removed from Letairis (ambrisentan) tablets. FDA, March 2011
58. McLaughlin VV, Oudiz RJ, Frost A et al: Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med, 2006; 174: 1257-63
59. Hoeper MM, Leuchte H, Halank M et al: Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J, 2006; 28(4): 691-94
60. Simonneau G, Rubin LJ, Galie N et al: Addition of sildenafil to longterm intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med, 2008; 149(8): 521-30
61. Galie N, Brundage BH, Ghofrani HA et al: Tadalafil therapy for pulmonary arterial hypertension. Circulation, 2009; 119(22): 2894-903
62. Doyle RL, McCrory D, Channick RN et al: Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence based clinical practice guidelines. Chest, 2004; 126: 63S-71S
63. Klepetko W, Mayer E, Sandoval J et al: Interventional and surgical modalities of treatment for pulmonary arterial hypertension. JACC, 2004; 43(12): 73S-80S
64. Olsson JK, Zamanian RT, Feinstein JA et al: Surgical and interventional therapies for pulmonary arterial hypertension. Semin Respir Crit Care Med, 2005; 26(4): 417-28
65. Reichenberger F, Pepke-Zaba J, McNeil K et al: Atrial septostomy in the treatment of severe pulmonary arterial hypertension. Thorax, 2003; 58: 797-800
66. Rothman A, Sklansky M, Lucas V et al: Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. Am J Cardiol, 1999; 84(6): 682-86
67. Sandoval J, Gaspar J, Pulido T et al: Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. JACC, 1998; 32: 297-304
68. Trulock E, Edwards L, Taylor D et al: Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart-lung transplantation report - 2006. J Heart Lung Transplant, 2006; 25: 880-92
69. Cottini SR, Lerch N, De Perrot M et al: Risk factors for reperfusion injury after lung transplantation. Intensive Care Med, 2006; 32(4): 557-63
70. Choong CK, Sweet SC, Guthrie TJ et al: Repair of congenital heart lesions combined with lung transplantation for the treatment of severe pulmonary hypertension: a 13-year experience. J Thorac Cardiovasc Surg, 2005; 129: 661-69
71. Hoeper MM, Mayer E, Simonneau G et al: Chronic thromboembolic pulmonary hypertension. Circulation, 2006; 113: 2011-20
72. Hoeper MM, Barbera JA, Channick RN et al: Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension, JACC, 2009; 54: S85-S96